{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T12:58:52Z","timestamp":1792241932299,"version":"4.4.0"},"reference-count":99,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T00:00:00Z","timestamp":1373932800000},"content-version":"vor","delay-in-days":227,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal for Parasitology: Drugs and Drug Resistance"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1016\/j.ijpddr.2012.01.003","type":"journal-article","created":{"date-parts":[[2012,1,30]],"date-time":"2012-01-30T19:42:41Z","timestamp":1327952561000},"page":"11-19","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":208,"special_numbering":"C","title":["Visceral leishmaniasis treatment: What do we have, what do we need and how to deliver it?"],"prefix":"10.1016","volume":"2","author":[{"given":"Lucio H.","family":"Freitas-Junior","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Chatelain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena Andrade","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jair L.","family":"Siqueira-Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijpddr.2012.01.003_b0005","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/nrd2684","article-title":"Genomic-scale prioritization of drug targets: the TDR targets database","volume":"7","author":"Aguero","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0010","first-page":"224","article-title":"Chemotherapy in the treatment and control of leishmaniasis","volume":"61","author":"Alvar","year":"2006","journal-title":"Adv. Parasitol."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0015","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1128\/AAC.49.9.3776-3783.2005","article-title":"Use of Leishmania donovani field isolates expressing the luciferase reporter gene in in vitro drug screening","volume":"49","author":"Ashutosh","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0020","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1099\/jmm.0.46841-0","article-title":"Molecular mechanisms of antimony resistance in Leishmania","volume":"56","author":"Ashutosh","year":"2007","journal-title":"J. Med. Microbiol."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0025","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0166-6851(00)00234-6","article-title":"Putrescine and spermidine transport in Leishmania","volume":"109","author":"Basselin","year":"2000","journal-title":"Mol. Biochem. Parasitol."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0030","first-page":"25","article-title":"Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries","volume":"76","author":"Berman","year":"1998","journal-title":"Bull. World Health Organ."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0035","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1086\/380638","article-title":"Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India","volume":"38","author":"Bhattacharya","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0040","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s00216-010-3788-3","article-title":"The beautiful cell: high-content screening in drug discovery","volume":"398","author":"Bickle","year":"2010","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0045","doi-asserted-by":"crossref","first-page":"600","DOI":"10.4269\/ajtmh.2005.72.600","article-title":"Colorimetric assay for screening compounds against Leishmania amastigotes grown in macrophages","volume":"72","author":"Buckner","year":"2005","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0050","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1517\/17460441.2011.602063","article-title":"Report of the 2nd chagas drug discovery consortium meeting, held on 3 Novermber 2010","volume":"6","author":"Bustamante","year":"2011","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0520","doi-asserted-by":"crossref","first-page":"4202","DOI":"10.1128\/AAC.00520-11","article-title":"The 8-aminoquinoline analogue sitamaquine causes oxidative stress in Leishmania donovani promastigotes by targeting succinate dehydrogenase","volume":"55","author":"Carvalho","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0055","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0006-291X(88)80081-0","article-title":"Mode of action of pentavalent antimonials: specific inhibition of type I DNA topoisomerase of Leishmania donovani","volume":"152","author":"Chakraborty","year":"1988","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0070","first-page":"189","article-title":"Antileishmanial activity of selected compounds in dogs experimentally infected with Leishmania donovani","volume":"21","author":"Chapman","year":"1979","journal-title":"Rev. Inst. Med. Trop. Sao Paulo"},{"key":"10.1016\/j.ijpddr.2012.01.003_b0060","doi-asserted-by":"crossref","first-page":"740","DOI":"10.2307\/3280460","article-title":"Visceral leishmaniasis in the squirrel monkey (Saimiri sciurea)","volume":"67","author":"Chapman","year":"1981","journal-title":"J. Parasitol."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0065","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/0035-9203(81)90032-8","article-title":"Leishmania donovani in the owl monkey (aotus trivirgatus)","volume":"75","author":"Chapman","year":"1981","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0075","first-page":"175","article-title":"Drug discovery and development for neglected diseases: the DNDi model","volume":"5","author":"Chatelain","year":"2011","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0080","first-page":"304","article-title":"Paromomycin as a therapeutic substance for intestinal amebiasis and bacterial enteritis","volume":"7","author":"Courtney","year":"1959","journal-title":"Antibiot. Annu."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0095","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1016\/0006-2952(87)90543-0","article-title":"The activity of alkyl phosphorylcholines and related derivatives against Leishmania donovani","volume":"36","author":"Croft","year":"1987","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0085","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.pt.2003.09.008","article-title":"Leishmaniasis \u2013 current chemotherapy and recent advances in the search for novel drugs","volume":"19","author":"Croft","year":"2003","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0100","first-page":"399","article-title":"Current scenario of drug development for leishmaniasis","volume":"123","author":"Croft","year":"2006","journal-title":"Indian J. Med. Res."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0105","doi-asserted-by":"crossref","first-page":"e804","DOI":"10.1371\/journal.pntd.0000804","article-title":"Identification of attractive drug targets in neglected-disease pathogens using an in silico approach","volume":"4","author":"Crowther","year":"2010","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0110","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0166-6851(01)00213-4","article-title":"Pteridine salvage throughout the Leishmania infectious cycle: implications for antifolate chemotherapy","volume":"113","author":"Cunningham","year":"2001","journal-title":"Mol. Biochem. Parasitol."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0115","unstructured":"Curry, A., Brown, R., 2003. The target product profile as a planning tool in drug discovery research. PharmaTech, 67\u201371."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0120","doi-asserted-by":"crossref","first-page":"e1253","DOI":"10.1371\/journal.pntd.0001253","article-title":"A screen against Leishmania intracellular amastigotes: comparison to a promastigote screen and identification of a host cell-specific hit","volume":"5","author":"De Muylder","year":"2011","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0125","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1128\/AAC.48.1.100-103.2004","article-title":"Oral delivery of meglumine antimoniate-beta-cyclodextrin complex for treatment of leishmaniasis","volume":"48","author":"Demicheli","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0130","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1042\/BJ20040283","article-title":"Reduction of anti-leishmanial pentavalent antimonial drugs by a parasite-specific thiol-dependent reductase, TDR1","volume":"381","author":"Denton","year":"2004","journal-title":"Biochem. J."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0135","doi-asserted-by":"crossref","first-page":"685","DOI":"10.4269\/ajtmh.2001.65.685","article-title":"Phase 2 trial of WR6026, an orally administered 8-aminoquinoline, in the treatment of visceral leishmaniasis caused by Leishmania chagasi","volume":"65","author":"Dietze","year":"2001","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0140","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S1471-4922(02)02321-8","article-title":"Protein kinases as drug targets in parasitic protozoa","volume":"18","author":"Doerig","year":"2002","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0145","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/nrmicro862","article-title":"Antimicrobial pharmacodynamics: critical interactions of \u201cbug and drug\u201d","volume":"2","author":"Drusano","year":"2004","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0150","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0001-706X(99)00007-8","article-title":"Leishmania donovani: cellular and humoral immune responses in Indian langur monkeys, Presbytis entellus","volume":"73","author":"Dube","year":"1999","journal-title":"Acta Trop."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0155","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.pt.2010.04.012","article-title":"Collaborative actions in anti-trypanosomatid chemotherapy with partners from disease endemic areas","volume":"26","author":"Dujardin","year":"2010","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0160","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s10096-004-1113-9","article-title":"Pharmacokinetic and pharmacodynamic issues in the treatment of parasitic infections","volume":"23","author":"Edwards","year":"2004","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0165","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0014-4894(76)90069-2","article-title":"Leishmania donovani: acquired resistance to visceral leishmaniasis in the golden hamster","volume":"40","author":"Farrell","year":"1976","journal-title":"Exp. Parasitol."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0170","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1038\/ng1555","article-title":"Large-scale in vivo flux analysis shows rigidity and suboptimal performance of Bacillus subtilis metabolism","volume":"37","author":"Fischer","year":"2005","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0175","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.3390\/molecules14072317","article-title":"Pentavalent antimonials: new perspectives for old drugs","volume":"14","author":"Frezard","year":"2009","journal-title":"Molecules"},{"key":"10.1016\/j.ijpddr.2012.01.003_b0180","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/S0035-9203(96)90330-2","article-title":"Lipid formulations of amphotericin b in the treatment of experimental visceral leishmaniasis due to Leishmania infantum","volume":"90","author":"Gangneux","year":"1996","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0185","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/clinids\/18.1.83","article-title":"Pancreatitis induced by pentavalent antimonial agents during treatment of leishmaniasis","volume":"18","author":"Gasser","year":"1994","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0190","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1128\/iai.57.10.3091-3096.1989","article-title":"Comparison of T-cell responses in self-limiting versus progressive visceral Leishmania donovani infections in golden hamsters","volume":"57","author":"Gifawesen","year":"1989","journal-title":"Infect. Immun."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0195","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0925-4439(02)00088-1","article-title":"Inhibitors of dihydrofolate reductase in Leishmania and trypanosomes","volume":"1587","author":"Gilbert","year":"2002","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ijpddr.2012.01.003_b0200","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.2174\/156802611795429176","article-title":"Finding new hits in neglected disease projects: target or phenotypic based screening?","volume":"11","author":"Gilbert","year":"2011","journal-title":"Curr. Top Med. Chem."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0205","first-page":"27","article-title":"Visceral leishmaniasis: experimental models for drug discovery","volume":"133","author":"Gupta","year":"2011","journal-title":"Indian J. Med. Res."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0210","first-page":"91","article-title":"The cell cycle of parasitic protozoa: potential for chemotherapeutic exploitation","volume":"5","author":"Hammarton","year":"2003","journal-title":"Prog. Cell Cycle Res."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0215","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.drudis.2006.08.015","article-title":"High-content screening moves to the front of the line","volume":"11","author":"Haney","year":"2006","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ijpddr.2012.01.003_b0220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ymben.2007.09.003","article-title":"A critique of the molecular target-based drug discovery paradigm based on principles of metabolic control: advantages of pathway-based discovery","volume":"10","author":"Hellerstein","year":"2008","journal-title":"Metab. Eng."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0225","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1126\/science.1112680","article-title":"The genome of the kinetoplastid parasite, Leishmania major","volume":"309","author":"Ivens","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.ijpddr.2012.01.003_b0235","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.4269\/ajtmh.2005.73.1005","article-title":"A phase II dose-ranging study of sitamaquine for the treatment of visceral leishmaniasis in India","volume":"73","author":"Jha","year":"2005","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0240","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.molbiopara.2008.12.007","article-title":"Paromomycin: uptake and resistance in Leishmania donovani","volume":"164","author":"Jhingran","year":"2009","journal-title":"Mol. Biochem. Parasitol."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0245","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1177\/030098588402100113","article-title":"Visceral leishmaniasis in the German shepherd dog. I. Infection, clinical disease, and clinical pathology","volume":"21","author":"Keenan","year":"1984","journal-title":"Vet. Pathol."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0250","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.cbpa.2007.08.030","article-title":"Cell-based high-content screening of small-molecule libraries","volume":"11","author":"Korn","year":"2007","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0255","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1462-5822.2004.00468.x","article-title":"Bioluminescent Leishmania expressing luciferase for rapid and high throughput screening of drugs acting on amastigote-harbouring macrophages and for quantitative real-time monitoring of parasitism features in living mice","volume":"7","author":"Lang","year":"2005","journal-title":"Cell Microbiol."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0260","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.2174\/156802611796575902","article-title":"Sterol 14alpha-demethylase (CYP51) as a therapeutic target for human trypanosomiasis and leishmaniasis","volume":"11","author":"Lepesheva","year":"2011","journal-title":"Curr. Top Med. Chem."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0265","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00204-009-0485-0","article-title":"Genotoxic effects of the antileishmanial drug Glucantime","volume":"84","author":"Lima","year":"2010","journal-title":"Arch. Toxicol."},{"issue":"Suppl. 2","key":"10.1016\/j.ijpddr.2012.01.003_b0270","doi-asserted-by":"crossref","first-page":"S305","DOI":"10.1086\/513843","article-title":"Susceptibility to infectious diseases: Leishmania as a paradigm","volume":"179","author":"Locksley","year":"1999","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0275","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1128\/AAC.48.6.2056-2060.2004","article-title":"Comparative activities of the triterpene saponin maesabalide III and liposomal amphotericin B (AmBisome) against Leishmania donovani in hamsters","volume":"48","author":"Maes","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0280","first-page":"475","article-title":"High-throughput screening of amastigotes of Leishmania donovani clinical isolates against drugs using a colorimetric beta-lactamase assay","volume":"47","author":"Mandal","year":"2009","journal-title":"Indian J. Exp. Biol."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0285","doi-asserted-by":"crossref","unstructured":"Matoussi, N., Ameur, H.B., Amor, S.B., Fitouri, Z., Becher, S.B., 2007. Cardiotoxicity of n-methyl-glucamine antimoniate (Glucantime). A case report. Med. Mal. Infect. 37 (Suppl 3), S257\u2013S259.","DOI":"10.1016\/j.medmal.2007.08.001"},{"key":"10.1016\/j.ijpddr.2012.01.003_b0295","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.4049\/jimmunol.166.3.1912","article-title":"The hamster as a model of human visceral leishmaniasis: progressive disease and impaired generation of nitric oxide in the face of a prominent Th1-like cytokine response","volume":"166","author":"Melby","year":"2001","journal-title":"J. Immunol."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0300","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1297-9716-42-39","article-title":"Mechanisms of resistance and susceptibility to experimental visceral leishmaniosis: BALB\/c mouse versus Syrian hamster model","volume":"42","author":"Nieto","year":"2011","journal-title":"Vet. Res."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0305","first-page":"941","article-title":"Innovative lead discovery strategies for tropical diseases","volume":"5","author":"Nwaka","year":"2006","journal-title":"Nat. Rev."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0310","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/QCO.0b013e32833fca9d","article-title":"Drug combinations for visceral leishmaniasis","volume":"23","author":"Olliaro","year":"2010","journal-title":"Curr. Opin. Infect. Dis."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0315","doi-asserted-by":"crossref","first-page":"e962","DOI":"10.1371\/journal.pntd.0000962","article-title":"Identification of small molecule lead compounds for visceral leishmaniasis using a novel ex vivo splenic explant model system","volume":"5","author":"Osorio","year":"2011","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0320","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.drup.2004.07.002","article-title":"Leishmaniasis: drugs in the clinic, resistance and new developments","volume":"7","author":"Ouellette","year":"2004","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0325","first-page":"566","article-title":"A new antifungal antibiotic, amphotericin B","volume":"3","author":"Oura","year":"1955","journal-title":"Antibiot. Annu."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0330","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1128\/AAC.48.3.852-859.2004","article-title":"Miltefosine induces apoptosis-like death in Leishmania donovani promastigotes","volume":"48","author":"Paris","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0335","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.4049\/jimmunol.167.6.3391","article-title":"Sodium stibogluconate is a potent inhibitor of protein tyrosine phosphatases and augments cytokine responses in hemopoietic cell lines","volume":"167","author":"Pathak","year":"2001","journal-title":"J. Immunol."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0340","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/nrd2201","article-title":"Drugs for bad bugs: confronting the challenges of antibacterial discovery","volume":"6","author":"Payne","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0345","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/ng2053","article-title":"Comparative genomic analysis of three Leishmania species that cause diverse human disease","volume":"39","author":"Peacock","year":"2007","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0350","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1136\/pgmj.2006.047340corr1","article-title":"Leishmaniasis","volume":"83","author":"Piscopo","year":"2007","journal-title":"Postgrad. Med. J."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0355","first-page":"332","article-title":"Leishmanioses in the Mediterranean \u201cMidi\u201d: results of an ecologic survey","volume":"62","author":"Rioux","year":"1969","journal-title":"Bull. Soc. Pathol. Exot. Filiales"},{"key":"10.1016\/j.ijpddr.2012.01.003_b0360","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0166-6851(02)00280-3","article-title":"Fatty acid and sterol metabolism: potential antimicrobial targets in apicomplexan and trypanosomatid parasitic protozoa","volume":"126","author":"Roberts","year":"2003","journal-title":"Mol. Biochem. Parasitol."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0365","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.molbiopara.2008.12.012","article-title":"Whole-genome comparative RNA expression profiling of axenic and intracellular amastigote forms of Leishmania infantum","volume":"165","author":"Rochette","year":"2009","journal-title":"Mol. Biochem. Parasitol."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0370","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/BF02535557","article-title":"Therapeutic activity of ET-18-OCH3 and hexadecylphosphocholine against mammary tumors in BD-VI rats","volume":"22","author":"Scherf","year":"1987","journal-title":"Lipids"},{"key":"10.1016\/j.ijpddr.2012.01.003_b0375","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ijpharm.2006.01.048","article-title":"Improved targeting of antimony to the bone marrow of dogs using liposomes of reduced size","volume":"315","author":"Schettini","year":"2006","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0380","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/0035-9203(92)90151-2","article-title":"Aminosidine (paromomycin) in the treatment of leishmaniasis imported into the United Kingdom","volume":"86","author":"Scott","year":"1992","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0385","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1128\/AAC.50.1.73-79.2006","article-title":"In vitro and in vivo interactions between miltefosine and other antileishmanial drugs","volume":"50","author":"Seifert","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0390","unstructured":"Shahian, M., Alborzi, A., 2009. Effect of meglumine antimoniate on the pancreas during treatment of visceral leishmaniasis in children. Med. Sci. Monit. 15, CR290\u2013293."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0395","doi-asserted-by":"crossref","first-page":"e540","DOI":"10.1371\/journal.pntd.0000540","article-title":"Identification of potent chemotypes targeting Leishmania major using a high-throughput, low-stringency, computationally enhanced, small molecule screen","volume":"3","author":"Sharlow","year":"2009","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0400","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1093\/clinids\/19.6.1034","article-title":"Phase 2 efficacy trial of an oral 8-aminoquinoline (WR6026) for treatment of visceral leishmaniasis","volume":"19","author":"Sherwood","year":"1994","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0405","doi-asserted-by":"crossref","first-page":"400","DOI":"10.4269\/ajtmh.2004.71.400","article-title":"Short report: fluorescent Leishmania: application to anti-leishmanial drug testing","volume":"71","author":"Singh","year":"2004","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0410","doi-asserted-by":"crossref","first-page":"e675","DOI":"10.1371\/journal.pntd.0000675","article-title":"Antileishmanial high-throughput drug screening reveals drug candidates with new scaffolds","volume":"4","author":"Siqueira-Neto","year":"2010","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0415","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1046\/j.1365-3156.2001.00778.x","article-title":"Drug resistance in Indian visceral leishmaniasis","volume":"6","author":"Sundar","year":"2001","journal-title":"Trop. Med. Int. Health"},{"key":"10.1016\/j.ijpddr.2012.01.003_b0425","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1086\/380971","article-title":"Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations","volume":"38","author":"Sundar","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0420","first-page":"733","article-title":"Miltefosine in the treatment of leishmaniasis: clinical evidence for informed clinical risk management","volume":"3","author":"Sundar","year":"2007","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0430","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0140-6736(10)62050-8","article-title":"Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial","volume":"377","author":"Sundar","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ijpddr.2012.01.003_b0435","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nrd3480","article-title":"How were new medicines discovered?","volume":"10","author":"Swinney","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0440","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/nrd1632","article-title":"Recent advances with liposomes as pharmaceutical carriers","volume":"4","author":"Torchilin","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0445","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1574-695X.2007.00311.x","article-title":"Immune response to Leishmania: paradox rather than paradigm","volume":"51","author":"Tripathi","year":"2007","journal-title":"FEMS Immunol. Med. Microbiol."},{"issue":"Suppl","key":"10.1016\/j.ijpddr.2012.01.003_b0450","doi-asserted-by":"crossref","first-page":"S91","DOI":"10.1017\/S0031182097001194","article-title":"Lipid biosynthesis pathways as chemotherapeutic targets in kinetoplastid parasites","volume":"114","author":"Urbina","year":"1997","journal-title":"Parasitology"},{"key":"10.1016\/j.ijpddr.2012.01.003_b0455","doi-asserted-by":"crossref","first-page":"3855","DOI":"10.1128\/AAC.00548-09","article-title":"In vitro susceptibilities of Leishmania donovani promastigote and amastigote stages to antileishmanial reference drugs: practical relevance of stage-specific differences","volume":"53","author":"Vermeersch","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0460","doi-asserted-by":"crossref","first-page":"7146","DOI":"10.4049\/jimmunol.0803859","article-title":"Miltefosine promotes IFN-gamma-dominated anti-leishmanial immune response","volume":"182","author":"Wadhone","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0465","doi-asserted-by":"crossref","first-page":"e1033","DOI":"10.1371\/journal.pntd.0001033","article-title":"High throughput screens yield small molecule inhibitors of Leishmania CRK3:CYC6 cyclin-dependent kinase","volume":"5","author":"Walker","year":"2011","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0470","first-page":"1","article-title":"Control of the leishmaniases. Report of a WHO expert committee","volume":"793","author":"WHO","year":"1990","journal-title":"World Health Organ. Tech. Rep. Ser."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0475","unstructured":"WHO, 2007. Report of the Fifth Consultative Meeting on Leishmania\/HIV Coinfection."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0480","unstructured":"WHO, 2010. Control of the leishmaniases. World Health Organ. Tech. Rep. Ser. xii\u2013xiii, 1\u2013186 (back cover)."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0485","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/sj.clpt.6100014","article-title":"Drug development and the FDA\u2019s critical path initiative","volume":"81","author":"Woosley","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0490","doi-asserted-by":"crossref","first-page":"39925","DOI":"10.1074\/jbc.M405635200","article-title":"Dual action of antimonial drugs on thiol redox metabolism in the human pathogen Leishmania donovani","volume":"279","author":"Wyllie","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0500","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1128\/AAC.41.4.752","article-title":"Activity of liposomal amphotericin B against experimental cutaneous leishmaniasis","volume":"41","author":"Yardley","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0510","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1179\/000349804X3171","article-title":"Effect of renal impairment on the pharmacokinetics of antimony in hamsters","volume":"98","author":"Zaghloul","year":"2004","journal-title":"Ann. Trop. Med. Parasitol."},{"key":"10.1016\/j.ijpddr.2012.01.003_b0515","doi-asserted-by":"crossref","first-page":"37445","DOI":"10.1074\/jbc.M404383200","article-title":"Leishmania major LmACR2 is a pentavalent antimony reductase that confers sensitivity to the drug pentostam","volume":"279","author":"Zhou","year":"2004","journal-title":"J. Biol. Chem."}],"container-title":["International Journal for Parasitology: Drugs and Drug Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211320712000048?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211320712000048?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:45:41Z","timestamp":1761921941000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211320712000048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":99,"alternative-id":["S2211320712000048"],"URL":"https:\/\/doi.org\/10.1016\/j.ijpddr.2012.01.003","relation":{},"ISSN":["2211-3207"],"issn-type":[{"value":"2211-3207","type":"print"}],"subject":[],"published":{"date-parts":[[2012,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Visceral leishmaniasis treatment: What do we have, what do we need and how to deliver it?","name":"articletitle","label":"Article Title"},{"value":"International Journal for Parasitology: Drugs and Drug Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijpddr.2012.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Australian Society for Parasitology. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}